Latest high-throughput screening Stories
HAMILTON, N.J., Jan. 4, 2011 /PRNewswire/ -- VENENUM Biodesign, a drug discovery company that utilizes ultra-high throughput screening (UHTS) of its compound collection to identify hits against its novel disease-based targets or its partners' targets, announced today its relocation to a brand-new, state-of-the-art facility in Hamilton, NJ in Mercer County. VENENUM Biodesign was established with the mission to improve patients' lives through the discovery of new therapeutic compounds. They...
BellBrook Labs announced today that they have been awarded a fourth U.S. patent for their innovative line of Transcreener® HTS Assay kits. This new patent, U.S. 7,847,066, describes the invention of a universal assay for UDP-glycosyltransferases based on direct detection of UDP in a high-throughput format. Madison, WI (PRWEB) December 22, 2010 It was announced today that the U.S. Patent and Trademark Office has awarded BellBrook Labs' Transcreener® technology its fourth...
By Kim McDonald, UC San DiegoUsing an automated screening technique developed by pharmaceutical companies to find new drugs, a team of researchers from UC San Diego and three other research institutions has discovered a molecule with the most potent effects ever seen on the biological clock.Dubbed by the scientists "longdaysin," for its ability to dramatically slow down the biological clock, the new compound and the application of their screening method to the discovery of other...
DALLAS, November 12, 2010 /PRNewswire/ -- The 'Top 10 drug discovery technologies (http://www.marketsandmarkets.com/Market-Reports/drug-discovery-41.html) - strategic analysis and global forecasts (2010 to 2015)' analyzes the top 10 drug discovery technologies with respect to market drivers, opportunities and trends in the diverse geographical regions including North America, Europe, Asia and rest of the world. Browse market data tables and in-depth TOC on Top 10 drug discovery...
BellBrook Labs has developed a high-content tumor Cell Invasion Assay by expanding the capability of its proprietary iuvoâ„¢ Microconduit Array platform to assess three dimensional cell movement through extracellular matrix. The results of this research, recently published in the Journal of Biomolecular Screening (Vol 15, 2010, p. 1114-1151), showcase the ability of BellBrook's 3D ECM Invasion Assay Service to advance the exploration of new targets for anti-cancer drug development....
Scientists at The Scripps Research Institute have designed a new molecular test that will allow researchers to look for potential drugs targeting a human metabolic enzyme believed to stimulate the appetite and play a role in diabetes.The new test, which the scientists call a simple assay, will allow researchers to look through hundreds of thousands of compounds for those that have potential to block the action of an enzyme known as ghrelin O-acyltransferase (GOAT). If drugs can be found that...
SUNNYVALE, Calif., Sept. 14 /PRNewswire/ -- Molecular Devices, Inc., a long-time leader in bioanalytical systems for microplate analysis, today announced the launch of two new multi-mode detection platforms that expand its portfolio of microplate readers, enabling the company to meet all combinations of customer needs now and into the future. (Logo: http://photos.prnewswire.com/prnh/20100406/SF82092LOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20100406/SF82092LOGO) Both products will...
PARIS, July 19 /PRNewswire-FirstCall/ -- Cellectis bioresearch, a specialist in genome customization and a subsidiary of Cellectis (Alternext: ALCLS), today announced the publication of a scientific study describing a novel method, based on meganuclease-driven targeted integration, for the generation of stable cell lines compatible with high throughput screening (HTS)(1). The study demonstrated Cellectis bioresearch's technology to be faster, more reliable and efficient in deriving...
SEATTLE, June 29 /PRNewswire-FirstCall/ -- Omeros Corporation (Nasdaq: OMER) today announced that it has successfully identified compounds that interact with three orphan G protein-coupled receptors (GPCRs) linked to cancer, metabolic disorders and appetite control. This breakthrough demonstrates Omeros' unique capability to introduce a large number of new drug targets to the pharmaceutical industry, which could lead to the development of novel therapeutics across a wide range of diseases...
SUNNYVALE, Calif., April 6 /PRNewswire/ -- Today, Molecular Devices, Inc. announced that it will launch two new products--the IonWorks Barracuda System & the 96 Cell-Wash Head for the AquaMax 2000/4000 Microplate Washer--as well as its new Molecular Devices brand at the Society for Biomolecular Sciences (SBS) Annual Meeting in Phoenix, Arizona, April 13-16. The new Molecular Devices brand is focused on a serious commitment to meet customer needs and exceed customer expectations, and...
